Lonza launches new L7 PBMC Reprogramming Bundle

Lonza has launched its new L7 PBMC Reprogramming Bundle, a new addition to its L7 hPSC System.

The new offering is a streamlined and comprehensive platform for the generation of human induced pluripotent stem cells (hiPSCs) and the maintenance of stem cells from a variety of sources.

Designed to slot seamlessly into the existing L7 workflow, it enables researchers to reprogramme peripheral blood mononuclear cells (PBMCs) for use in downstream experiments.

It consists of the new L7 PBMC Priming-Recovery Kit, a number of PBMC-specific reprogramming enhancers and a source of human PBMCs for researchers to use as a positive control donor during their reprogramming experiments.

Dr Minh Hong, marketing manager at Lonza Bioscience Solutions, said: "The new L7 PBMC Reprogramming Bundle is a powerful addition to the L7 portfolio and is part of our ongoing commitment to develop the best tools for stem cell researchers."

Lonza is one of the world's leading and most trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets.